Novel broadly reactive monoclonal antibody protects against <i>Pseudomonas aeruginosa</i> infection.

ABSTRACT: The incidence of infections attributed to antimicrobial-resistant (AMR) pathogens has increased exponentially over the recent decades reaching 1.27 million deaths worldwide in 2019. Without intervention, these infections are predicted to cause up to 10 million deaths a year and incur costs of up to 100 trillion US dollars globally by 2050. The emergence of AMR bacteria such as the ESKAPEE pathogens, and in particular Pseudomonas aeruginosa and species from the genus Burkholderia, underscores an urgent need for new therapeutic strategies. Monoclonal antibody (mAb) therapy offers a promising alternative to treat and prevent bacterial infections. In this study, we used peptides from highly conserved areas of the bacterial flagellin to generate monoclonal antibodies capable of br

SUBMITTER: Mateu-Borras M 

PROVIDER: S-EPMC11784295 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature